Emcure Pharmaceuticals Limited posted a strong financial performance for the quarter ended March 31, 2025 (Q4 FY25), with net profit rising 63% year-on-year to ₹197.2 crore, compared to ₹121.0 crore in the same quarter last year.
The company’s revenue from operations grew 19.4% to ₹2,116.2 crore, up from ₹1,771.4 crore in Q4 FY24. Total income stood at ₹2,120.7 crore, against ₹1,783.7 crore last year.
EBITDA for the quarter rose to ₹402 crore, compared to ₹310 crore in Q4 FY24, reflecting a growth of 29.7% YoY. The EBITDA margin expanded to 19.01%, up from 17.5% a year earlier, indicating improved operational efficiency and cost controls.
Total expenses during the quarter increased to ₹1,849.7 crore, as against ₹1,616.7 crore in the same period last year. The rise in costs was driven by higher procurement and employee benefit expenses.
For the full year FY25, Emcure reported revenue of ₹7,896 crore, up from ₹6,658 crore in FY24, and net profit of ₹707.4 crore, compared to ₹527.6 crore in the previous year.
The company attributed the performance to strong growth in both domestic and international markets, improved product mix, and continued investment in R&D and new launches.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
